2002
But you can send us an email and we'll get back to you, asap.
Betapace [package insert].
... C07AA07 - sotalol : Belongs to the class of non-selective beta-blocking agents.
Lexi-Comp, Inc.; May 7, 2009.
Learn generic and trade name 2 with free interactive flashcards. This site does not dispense medical advice or advice of any kind. 2010 ceftin-zinacef-cefuroxime-342500 Drugs Drugs cefuroxime 2002 174012-overview Diseases & Conditions Your list will be saved and can be edited at any time.The above information is provided for general
provider for the most current information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information. 2002
Diseases & Conditions
Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2007 April.Lexi-Interact [computer program].
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
Please confirm that you would like to log out of Medscape. eMedTV serves only as an informational resource.
Contact Us.
It comes as tablets (immediate-release and extended-release) and as a liquid suspension.
500-750 mg IV q8hr; switch to oral therapy as soon as clinically possible750 mg IV/IM q8hr; switch to oral therapy as soon as clinically possible750 mg IV/IM q8hr; switch to oral therapy as soon as clinically possibleUncomplicated: 1 g PO once or 1.5 g IM once at 2 different sites with 1 g probenecid PO1.5 g IV/IM q8hr; may be administered q6hr in life-threatening situations3 months-12 years: 30 mg/kg/day suspension PO divided q12hr for 10 days; not to exceed 1000 mg/day; alternatively, 75-150 mg/kg/day IV/IM divided q8hr; not to exceed 6 g/day 3 months-12 years: 30 mg/kg/day suspension PO divided q12hr for 10 days; not to exceed 1000 mg/day; alternatively, 75-150 mg/kg/day IV/IM divided q8hr; not to exceed 6 g/day 3 months-12 years: 30 mg/kg/day suspension PO divided q12hr for 10 days; not to exceed 1000 mg/day or 75-100mg/kg/day IV/IM divided q8hr; not to exceed 6 g/day 3 months-12 years: 20 mg/kg/day PO divided q12hr for 10 days; not to exceed 500 mg/day or 75-150 mg/kg/day IV/IM divided q8hr; not to exceed 6 g/day Increase in blood urea nitrogen (BUN) and creatinineProlonged prothrombin time (PT)/international normalized ratio (INR)Prolonged INR in nutritionally deficient patients, prolonged treatment, and hepatic and renal disease reportedFilm-coated tablet and oral solution are not bioequivalent; tablets should not be crushedUse caution in patients with history of colitis, renal impairment, or with a history of seizure disordersUse with caution in patients with history of penicillin allergyReduce dosage by 50% if CrCl is 10-30 mL/min and by 75% if CrCl <10 mL/min (high doses may cause CNS toxicity)Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapyAvailable data from published epidemiologic studies, case series, and case reports over several decades in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomesBased on several published case reports describing multiple lactating women receiving therapy via intravenous, intramuscular, and oral routes, drug is present in human milk; the highest maternal milk concentration described occurred in lactating women 8 hours after an intramuscular administration of 750 mg; allowing for an infant milk consumption of 150 mL/kg/day, the estimated breastfed infant dose would be less than 1% of adult doseNo data are available on effects of drug on breastfed infant or on milk production; developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal conditionA: Generally acceptable.
Contact the applicable plan
informational and educational purposes only.